Events
HBV Forum 8 – Hepatitis B
21 June, 2022
London, UK
ENYO Pharma was attending HBV Forum 8 in London. The HBV Forum aims to advance the regulatory science for novel HBV therapeutic interventions and its associated morbidities in real time by providing an independent and neutral environment for ongoing multi-stakeholder dialogue.
EIC Growth Club – Tech Tour Health 2022
20-22 June, 2022
Lausanne, Switzerland
ENYO Pharma was participating as a member of the EIC Growth Club in Tech Tour Health 2022 to secure growth, exchange international contacts and build long-lasting relations with some of the most active investors and other innovators in Healthcare space.
https://techtour.com/events/2022/6/event-tech-tour-health-2022%5B2%5D.html
AASLD-EASL HBV Endpoints 2022
3-4 June, 2022
Washington, US
ENYO Pharma was attending AASLD-EASL HBV Endpoints 2022 to share news on therapeutic endpoints, trial designs and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D. It was a great opportunity to meet academic, regulatory, pharmaceutical communities and patients in liver disease area.
The Science of HBV Cure Meeting
30 May-2 June, 2022
Hybrid event-Singapour
ENYO Pharma and its collaborators were presenting the last results on Vonafexor’s effect in HBV at The Science of HBV Cure Meeting organized by Singapore Hepatology Conference.
“Antiviral effects of oral farnesoid X receptor agonist Vonafexor combined with pegylated interferon alpha2a in untreated patients with chronic hepatitis B”.
The 22nd Bio€quity Europe
16-18 May, 2022
Milan, Italy
ENYO Pharma will attend the 22nd Bio€quity Europe, the Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs.
ENYO Pharma’s team will reconnect with investors and partners to accelerate the clinical development of its lead compound Vonafexor focused on kidney and liver diseases.
Jacky Vonderscher will also present “VONAFEXOR, a fibrolytic and anti-inflammatory for the treatment of kidney and liver diseases” in the Hot Topics Track #1 session,
Latest Press Release 